Blog

Tech Nation Visa: the gateway to world-leading UK tech jobs

At BenevolentAI we are always on the lookout for exceptional people to join us on our mission to re-engineer drug discovery and deliver life changing medicines to patients.


Our teams are curious, open to new ideas and passionate about making a positive impact on the world. At BenevolentAI we value different experiences, skills, and backgrounds and believe a diverse and inclusive environment is necessary to push technological and scientific boundaries. 

A globally diverse perspective is important, which is why we encourage the best tech talent from around the world to join us. As such, we want to draw attention to the Tech Nation Visa, also known as the Global Talent Visa in digital technology, which is a great initiative that enables the brightest international talent to live and work in the UK. 

Tech Nation, a close partner of BenevolentAI, has been designated by the Home Office to endorse applications for this Visa.  The application process is based on your unique background, skills, and achievements and there are two pathways to apply, depending on your experience:  Exceptional Talent and Exceptional Promise. The Tech Nation visa is highly flexible, not tied to a specific job, company or location. Applicants can have experience in any tech subsector and either business or technical backgrounds. It is granted for up to 5 years, with the ability to extend as many times as required. The Tech Nation Visa can also lead to permanent residency here in the UK.

Whether you have an established career in tech, or are finding your feet, the UK’s flourishing tech scene provides rich opportunities for entrepreneurs to set up or scale a business, or find employment at an existing firm. 52% of those endorsed last year by Tech Nation are now employed at leading UK tech firms, helping to fill existing talent gaps, while 28% have launched their own businesses. 

At BenevolentAI you have the chance to work alongside our world-leading experts, building tech which has real impact and contributes directly to our mission to improve patients’ lives. If you are a talented and creative individual interested in joining us on this mission, this could be your answer. 

Start building your career today, and find out more on the Tech Nation Visa guide here. 

Best of luck in your application.

The BenevolentAI Team


More Posts

You Might Also Like

News
BenevolentAI to present at 41st Annual J.P. Morgan Healthcare Conference
BenevolentAI ​​(Euronext Amsterdam: BAI), a leading clinical-stage AI drug discovery company, announces that it will participate in the upcoming 41st Annual J.P. Morgan Healthcare Conference in San Francisco, US from 9-12 January 2023.
Dec 1, 2022
Blog
FAIR Data Foundation: An Enabler for AI Drug Discovery
Biomedical data used in AI-enabled drug discovery should adhere to the FAIR Data Principles — Findability, Accessibility, Interoperability and Reusability. This blog explains why this is, how one can make data FAIR and challenges that remain.
Nov 8, 2022
News
BenevolentAI to present at Jefferies Investor Conference in November
BenevolentAI’s Investor Relations and Business Development team will be attending the Jefferies Healthcare London conference, with Nick Keher, CFO, presenting on Thursday 17th November.
Nov 4, 2022
News
BenevolentAI achieves further milestones in AI-enabled target identification collaboration with AstraZeneca
Two additional AI-generated novel targets selected by AstraZeneca for its drug development portfolio, resulting in two milestone payments for BenevolentAI.
Oct 6, 2022
News
Interim results for the six months ended 30 June 2022
Continued operational progress and strengthened financial position provides capital for key value inflection points and continued investment in leading technology platform.
Sep 27, 2022
News
Analyst / Investor Event
BenevolentAI announces that during its analyst / investor event and interim results presentation being held in London today, new information on the Company’s BEN-2293 Phase Ib study results will be disclosed.
Sep 27, 2022